Swiss Equities: one domicile, three different fundamental profiles
Novartis, UBS, and Logitech compared side by side across the latest five reported fiscal years, with company-specific margins, leverage, cyclicality, and scenario exposure shown directly rather than averaged into a single “Swiss exposure” series.
These filings do not support treating the three names as one homogeneous Swiss allocation. Novartis reads as the defensive growth engine: steadier top-line progression, very high gross margins, and improving operating profitability. UBS is a different kind of exposure entirely, with fee-led banking economics layered onto a highly levered balance sheet. Logitech adds the clearest cyclical hardware profile, with the sharpest revenue reset and a later recovery path.
The overlap across the trio sits more in macro valuation factors such as CHF moves and global risk sentiment than in their operating fundamentals. That means the basket provides some diversification, but not enough to justify collapsing it into a single “safe-haven Swiss” narrative.
- Logitech fiscal years end in March; Novartis and UBS fiscal years end in December.
- UBS operating-profit comparisons use a pre-tax profit proxy from the extracted CSVs and concept mapping.
- Novartis and Logitech revenue lines reflect product-sales concepts; UBS uses a banking top-line concept, so revenue mix is economically different.
- Single-year net margins, especially for UBS and Novartis, contain accounting noise; operating trends and leverage are more decision-useful.
The latest numbers point to very different transmission channels if a major geopolitical agreement reshapes supply chains and changes rate or currency expectations. The panel below keeps the qualitative read compact and anchored to the extracted metrics already visible elsewhere in the dashboard.
| Company | Sector | Latest period | Latest revenue | Revenue CAGR | Growth volatility | Gross margin | Operating margin | Net margin | Assets / equity | Mix / caveat |
|---|
Yes, but mostly because they are three sectors with different operating engines, not because they share a Swiss domicile. Novartis adds defensive demand and margin resilience; Logitech adds cyclical consumer-electronics and supply-chain exposure; UBS adds financials exposure tied to rates, wealth activity, and balance-sheet marks.
The overlap is real at the valuation layer: CHF moves, broad global risk sentiment, and multinational translation effects can still pull all three at once. That overlap limits the case for calling the trio a fully independent set of risks.
A sector-diversification portfolio can use all three, but the data points toward unequal sizing rather than equal-weight treatment. The clearest hierarchy is highest weight to Novartis, meaningful but smaller exposure to Logitech, and a capped allocation to UBS.